XeriJect is a disruptive platform that addresses the problem of injection with a non-aqueous reformulation of existing biopharmaceuticals. This platform creates highly concentrated pastes or viscous liquids, which can be packaged into an auto-injector pen for rapid and easy administration. For severe hypoglycemia, Xeris has created a non-aqueous glucagon formulation to develop a Glucagon Rescue Pen (GRP) akin to the EpiPen for allergic reactions.
Xeris Pharmaceuticals is currently undergoing clinical trials for its product. Since participating in the TVL accelerator, the company has raised $9.8 million in venture funding.
For more information, visit